Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for
LaserBodySculpting(SM)
- High Power System Combines Clinical Benefits of Dual Wavelengths Through
Patented MultiPlex(TM) Technology
WESTFORD, Mass., April 28 /PRNewswire-FirstCall/ -- Cynosure, Inc.
(Nasdaq: CYNO), a leading developer and manufacturer of a broad array of
light-based aesthetic treatment systems, today announced the introduction of
Smartlipo MPX, the next generation of the company's award-winning family of
workstations for laser lipolysis. Smartlipo MPX is the only FDA-cleared,
dual-wavelength laser system designed to efficiently liquefy fat and tighten
skin through collagen remodeling. Smartlipo MPX will premier at the American
Society for Aesthetic Plastic Surgery's 41st Annual Meeting May 2-6, 2008 in
San Diego, CA.
The novel Smartlipo MPX platform utilizes the Company's patented MultiPlex
technology to combine the benefits of the 1064-nm and 1320-nm wavelengths in
one laser output. MultiPlex technology enables the workstation's two
wavelengths to be blended, or fired sequentially, for optimal fat liquefaction
and skin tightening results. The two wavelengths can also be used individually
and each offers unique characteristics. The 20 watt 1064-nm wavelength
disrupts a broad region of tissue while heating the treated areas evenly. The
1064-nm wavelength also mediates blood vessel coagulation enhancing
hemostasis.
The 12 watt 1320-nm wavelength is highly concentrated with minimal scatter,
and is rapidly absorbed by the water in the tissue. The combination of the two
wavelengths creates a blended thermal and photomechanical effect that
efficiently liquefies fat and tightens skin through collagen remodeling.
"Since we launched Smartlipo in early 2007, the treatment quality and
safety of our system has helped to establish this product as the standard for
laser lipolysis in the U.S.," said Cynosure President and Chief Executive
Officer Michael Davin. "Now we aim to replicate that success with Smartlipo
MPX. We expect to introduce the product to our domestic customer base this
quarter, and internationally in the second half of this year, beginning with
select international markets. We believe customers worldwide will be excited
about Smartlipo MPX's unique blended dual-wavelength technology, which allows
physicians to customize their treatment protocol based on the specific needs
of individual patients."
"The combination of wavelengths in the Smartlipo MPX is very effective for
the laser lipolysis patient," said Barry DiBernardo, M.D., Medical Director of
New Jersey Plastic Surgery in Montclair, N.J. Dr. DiBernardo has been selected
as a featured speaker at the American Society for Aesthetic Plastic Surgery's
meeting, where he will discuss his clinical experience with the Smartlipo MPX
in a "Best of Hot Topics" panel discussion. "By virtue of the MultiPlex
component, Smartlipo MPX emits the wavelengths individually or sequentially.
In performing laser lipolysis, it's important to heat the skin gradually to
ensure patient safety. The blending of the two wavelengths together provides
us a very gradual and safer slope to achieve our goal skin temperature, which
allows for a more uniform delivery of laser energy, enhancing both the
efficacy and safety profile of the system."
"While the Smartlipo MPX model is geared toward dermatologists and plastic
surgeons that focus on a high volume of liposuction procedures, the
single-wavelength 18 watt system remains an excellent option for those who
want to incorporate laser lipolysis into their practice," Davin said.
"Cynosure will continue to offer and fully support our single wavelength
Smartlipo system. Going forward, we will work with all of our current and
prospective Smartlipo customers on an individual basis to determine the
LaserBodySculpting technology that best fits their practice."
How Smartlipo MPX Works
As with the original Smartlipo Workstation, Smartlipo MPX is a minimally
invasive laser lipolysis system. The system's proprietary pulsing format
delivers laser energy through a cannula to liquefy the fat, which is then
removed from the body. The laser energy also coagulates the tissue, thereby
sculpting body contours and tightening the skin. The procedure generally
causes less bleeding, swelling and bruising than traditional liposuction,
resulting in fewer complications and faster recovery. Cynosure received U.S.
Food and Drug Administration clearance to market Smartlipo in the fourth
quarter of 2006.
Smartlipo MPX can be configured with Cynosure's recently introduced
proprietary SmartSense(TM) intelligent delivery system. SmartSense features an
advanced microchip, the Accelerometer, which is inserted into the intelligent
handpiece, to ensure the precise level of energy is delivered based on the
area of treatment and predetermined settings in conjunction with the motion of
the handpiece. SmartSense ensures patient safety, automatically shutting down
the laser within two-tenths of a second after motion of the handpiece stops.
"The introduction of Smartlipo MPX extends Cynosure's position as the
recognized market leader in laser lipolysis technology," Davin said. "We are
committed to providing our industry with the safest and most efficacious
aesthetic technology possible, and we believe that Smartlipo MPX with
SmartSense delivers on both fronts. To continue to broaden adoption of our
technology, through the remainder of 2008 we plan to present numerous peer
reviewed clinical studies that evaluate treatment optimization and explore
potential new indications. Complementing our clinical initiatives, we are
conducting a comprehensive training and education program designed to help our
customers provide the best possible patient experience."
About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems that are
used by physicians and other practitioners to perform non-invasive and
minimally invasive procedures to remove hair, treat vascular lesions,
rejuvenate skin through the treatment of shallow vascular and pigmented
lesions, laser lipolysis and temporarily reduce the appearance of cellulite.
Cynosure's products include a broad range of laser and other light-based
energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as
well as intense pulsed light. Cynosure was founded in 1991.
For corporate or product information, contact Cynosure at 800-886-2966, or
visit http://www.cynosure.com.
Safe Harbor
Any statements in this press release about future expectations, plans and
prospects for Cynosure, Inc., including statements about the company's
expectations regarding the performance and market acceptance of the Smartlipo
MPX and future financial performance, as well as other statements containing
the words "believes," "anticipates," "plans," "expects," "will" and similar
expressions, constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements as a result
of various important factors, including market acceptance of the Smartlipo
MPX,
Cynosure's reliance on sole source suppliers, the inability to accurately
predict the timing or outcome of regulatory decisions, changes in consumer
preferences, competition in the aesthetic laser industry, economic, market,
technological and other factors discussed in Cynosure's most recent Annual
Report on Form 10-K, which is filed with the Securities and Exchange
Commission. In addition, the forward-looking statements included in this press
release represent Cynosure's views as of the date of this press release.
Cynosure anticipates that subsequent events and developments will cause its
views to change. However, while Cynosure may elect to update these forward-
looking statements at some point in the future, it specifically disclaims any
obligation to do so. These forward-looking statements should not be relied
upon as representing Cynosure's views as of any date subsequent to the date of
this press release.
SOURCE Cynosure, Inc.
Scott Solomon, Vice President of Sharon Merrill Associates, Inc. for Cynosure,
Inc., +1-617-542-5300, ssolomon@investorrelations.com
